- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07687459
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).
In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Qinhan Chen
- Telefonní číslo: +86 021-50831718
- E-mail: Insilico-Clinicaltrial@insilico.ai
Studijní místa
-
-
Anhui
-
Hefei, Anhui, Čína
- Zatím nenabíráme
- Anhui Provincial Hospital
-
Hefei, Anhui, Čína
- Zatím nenabíráme
- Anhui Chest Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína
- Nábor
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Čína
- Nábor
- Beijing Friendship hospital, Capital Medical University
-
Beijing, Beijing Municipality, Čína
- Zatím nenabíráme
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, Čína
- Zatím nenabíráme
- Fuzhou University Affiliated Provincial Hospital
-
Xiamen, Fujian, Čína
- Nábor
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, Čína
- Nábor
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, Čína
- Zatím nenabíráme
- Nanfang Hospital, Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, Čína
- Zatím nenabíráme
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hainan
-
Haikou, Hainan, Čína
- Nábor
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, Čína
- Zatím nenabíráme
- The Second Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, Čína
- Zatím nenabíráme
- Hebei Medical University Third Hospital
-
-
Henan
-
Anyang, Henan, Čína
- Nábor
- The People's Hospital of Anyang City
-
Nanyang, Henan, Čína
- Nábor
- Nanyang First People's Hospital
-
Zhengzhou, Henan, Čína
- Zatím nenabíráme
- Henan Provincial People's Hospital
-
Zhengzhou, Henan, Čína
- Zatím nenabíráme
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Čína
- Zatím nenabíráme
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, Čína
- Zatím nenabíráme
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Yichang, Hubei, Čína
- Zatím nenabíráme
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha, Hunan, Čína
- Zatím nenabíráme
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, Čína
- Zatím nenabíráme
- The Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, Čína
- Zatím nenabíráme
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína
- Nábor
- Nanjing Drum Tower Hospital
-
Xuzhou, Jiangsu, Čína
- Zatím nenabíráme
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, Čína
- Zatím nenabíráme
- Jiangxi Provincial People' Hospital
-
-
Jilin
-
Changchun, Jilin, Čína
- Zatím nenabíráme
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, Čína
- Zatím nenabíráme
- Shengjing Hospital of China Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, Čína
- Nábor
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shaanxi, Čína
- Nábor
- The First Affiliated Hospital of Xi'an Medical College
-
-
Shandong
-
Jinan, Shandong, Čína
- Zatím nenabíráme
- Qilu Hospital of Shandong University
-
Jinan, Shandong, Čína
- Zatím nenabíráme
- Introduction of the First Affiliated Hospital of Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína
- Nábor
- Shanghai Pulmonary Hospital Affiliated to Tongji University
-
-
Shanxi
-
Taiyuan, Shanxi, Čína
- Zatím nenabíráme
- Shanxi Bethune Hospital
-
Yuncheng, Shanxi, Čína
- Zatím nenabíráme
- Yuncheng Central Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Čína
- Zatím nenabíráme
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, Čína
- Zatím nenabíráme
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Čína
- Zatím nenabíráme
- Tianjin Medical University General Hospital
-
Tianjin, Tianjin Municipality, Čína
- Zatím nenabíráme
- Tianjin Chest Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, Čína
- Zatím nenabíráme
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, Čína
- Zatím nenabíráme
- The First People Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína
- Zatím nenabíráme
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Čína
- Nábor
- Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
-
Jiaxing, Zhejiang, Čína
- Zatím nenabíráme
- The First Hospital of Jiaxing
-
Ningbo, Zhejiang, Čína
- Zatím nenabíráme
- Ningbo Medical Center Lihuili Hospital
-
Ningbo, Zhejiang, Čína
- Zatím nenabíráme
- The First Affiliated Hospital of Ningbo University
-
Wenzhou, Zhejiang, Čína
- Zatím nenabíráme
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
- Patients aged ≥40 years at time of signing the ICF.
- Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
- UIP or probable UIP with fibrosis extent >10% at HRCT.
Meet all the following criteria during the screening period:
- FVC ≥45% predicted of normal
- FEV1/FVC ≥0.7
- DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
Background antifibrotic therapies are allowed, patients may be either:
- on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
- not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
- Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
- Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
Exclusion criteria:
- Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
- Previous participation in a clinical study with rentosertib (active or placebo).
- Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
- Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
- Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
- Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
- Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
- Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
- Patients with Gilbert's disease
- Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
- Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
- Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
- Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
- Patient with a history of lung volume reduction surgery or lung transplant.
- Current smoker and/or cotinine (smoking) test positive.
- History of drug abuse, drug use, or alcohol abuse within the past 3 months.
- Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
- Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
- Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
- Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
- Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
- Medications associated with substantial risk for prolongation of corrected QT interval.
- Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
- Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
- Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
- Any condition that would interfere with the interpretation of study assessments or impair study participation.
- Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
|
Dosage form: Tablets; Frequency of administration: Orally QD.
Other Names: Rentosertib
|
|
Komparátor placeba: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
|
Dávková forma: Tableta; Frekvence podání: Orálně QD.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Časové okno: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
time to first occurrence of any disease progression
Časové okno: up to 52 weeks
|
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
|
up to 52 weeks
|
|
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Časové okno: week 52
|
week 52
|
|
|
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Časové okno: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Časové okno: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Časové okno: Weeks 0, 52
|
Weeks 0, 52
|
Další výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Časové okno: up to 56 weeks
|
up to 56 weeks
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Časové okno: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Časové okno: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Časové okno: weeks 0, 12 ,26, and 52
|
weeks 0, 12 ,26, and 52
|
|
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Časové okno: weeks 0, 52
|
weeks 0, 52
|
|
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Časové okno: weeks 0, 52
|
weeks 0, 52
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- INS018-055-301
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .